Globus Medical (GMED) 10-Q 4 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 02, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Jun. 30, 2021
Entity Registrant Name	GLOBUS MEDICAL, INC.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		100,890,673
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Class A Common Stock, par value $.001 per share
Trading Symbol	GMED
Security Exchange Name	NYSE
Entity File Number	001-35621
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3744954
Entity Address, Address Line One	2560 General Armistead Avenue
Entity Address, City or Town	Audubon
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19403
City Area Code	610
Local Phone Number	930-1800
Document Quarterly Report	true
Document Transition Report	false
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001237831
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash, cash equivalents, and restricted cash	$ 268,783	$ 239,397
Short-term marketable securities	191,644	187,344
Accounts receivable, net of allowances of $4,687 and $4,408, respectively	165,852	141,676
Inventories	231,208	229,153
Prepaid expenses and other current assets	15,200	17,771
Income taxes receivable	19,311	6,424
Total current assets	891,998	821,765
Property and equipment, net of accumulated depreciation of $293,534 and $276,451, respectively	210,749	216,879
Long-term marketable securities	453,726	358,522
Intangible assets, net	76,153	86,949
Goodwill	155,777	156,716
Other assets	33,147	32,039
Deferred income taxes	8,663	6,615
Total assets	1,830,213	1,679,485
Current liabilities:
Accounts payable	21,270	18,205
Accrued expenses	78,453	78,334
Income taxes payable	3,427	1,101
Business acquisition liabilities	8,182	5,777
Deferred revenue	9,005	8,125
Payable to broker	9,705	9,250
Total current liabilities	130,042	120,792
Business acquisition liabilities, net of current portion	39,813	31,493
Deferred income taxes	5,474	6,202
Other liabilities	15,611	14,701
Total liabilities	190,940	173,188
Commitments and contingencies (Note 15)
Equity:
Additional paid-in capital	508,788	457,161
Accumulated other comprehensive income (loss)	(1,572)	3,955
Retained earnings	1,131,956	1,045,082
Total equity	1,639,273	1,506,297
Total liabilities and equity	1,830,213	1,679,485
Common Class A [Member]
Equity:
Common stock	79	77
Common Class B [Member]
Equity:
Common stock	$ 22	$ 22

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Accounts receivable, allowances	$ 4,687	$ 4,408
Property and equipment
Accumulated depreciation	$ 293,534	$ 276,451
Equity:
Common stock, shares authorized	775,000,000
Common Class A [Member]
Equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	78,303,475	77,284,007
Common stock, shares outstanding	78,303,475	77,284,007
Common Class B [Member]
Equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	22,430,097	22,430,097
Common stock, shares outstanding	22,430,097	22,430,097

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Consolidated Statements of Operations and Comprehensive Income [Abstract]
Net sales	$ 251,016	$ 148,922	$ 478,360	$ 339,499
Cost of goods sold	63,846	50,643	118,873	99,507
Gross profit	187,170	98,279	359,487	239,992
Operating expenses:
Research and development	15,547	39,455	30,471	54,857
Selling, general and administrative	107,254	80,019	205,145	173,558
Provision for litigation		197	(94)	197
Amortization of intangibles	4,623	4,115	9,397	7,891
Acquisition related costs	13,870	56	14,144	604
Total operating expenses	141,294	123,842	259,063	237,107
Operating income/(loss)	45,876	(25,563)	100,424	2,885
Other income/(expense), net
Interest income/(expense), net	2,541	3,590	5,253	7,914
Foreign currency transaction gain/(loss)	209	(168)	(71)	(636)
Other income/(expense)	307	199	521	393
Total other income/(expense), net	3,057	3,621	5,703	7,671
Income/(loss) before income taxes	48,933	(21,942)	106,127	10,556
Income tax provision	7,388	(1,105)	19,253	5,444
Net income/(loss)	41,545	(20,837)	86,874	5,112
Other comprehensive income/(loss):
Unrealized gain/(loss) on marketable securities, net of tax	(774)	6,897	(2,440)	3,055
Foreign currency translation gain/(loss)	1,026	667	(3,087)	1,141
Total other comprehensive income/(loss)	252	7,564	(5,527)	4,196
Comprehensive income/(loss)	$ 41,797	$ (13,273)	$ 81,347	$ 9,308
Earnings per share:
Basic	$ 0.41	$ (0.21)	$ 0.87	$ 0.05
Diluted	$ 0.40	$ (0.21)	$ 0.84	$ 0.05
Weighted average shares outstanding:
Basic	100,449	97,509	100,159	98,572
Diluted	103,475	97,509	102,931	100,992

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]Common Class A [Member]	Common Stock [Member]Common Class B [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Retained Earnings [Member]	Total
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			77,394	22,431
Total equity, beginning of period at Dec. 31, 2019			$ 77	$ 22	$ 357,320	$ (2,898)	$ 1,047,931	$ 1,402,452
Stock-based compensation					6,902			6,902
Exercise of stock options (shares)			190
Exercise of stock options			$ 1		5,762			5,763
Comprehensive income/(loss)						(3,368)	25,949	22,581
Repurchase and retirement of common stock (shares)			(1,920)
Repurchase and retirement of common stock			$ (2)				(73,862)	(73,864)
Total equity, end of period at Mar. 31, 2020	$ (468)	$ (468)	$ 76	$ 22	369,984	(6,266)	999,550	1,363,366
Shares, Outstanding, Ending Balance at Mar. 31, 2020			75,664	22,431
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			77,394	22,431
Total equity, beginning of period at Dec. 31, 2019			$ 77	$ 22	357,320	(2,898)	1,047,931	1,402,452
Comprehensive income/(loss)								9,308
Total equity, end of period at Jun. 30, 2020			$ 75	$ 22	387,611	1,298	947,909	1,336,915
Shares, Outstanding, Ending Balance at Jun. 30, 2020			75,327	22,430
Shares, Outstanding, Beginning Balance at Mar. 31, 2020			75,664	22,431
Total equity, beginning of period at Mar. 31, 2020	$ (468)	$ (468)	$ 76	$ 22	369,984	(6,266)	999,550	1,363,366
Stock-based compensation					7,426			7,426
Exercise of stock options (shares)			434
Exercise of stock options (shares)				(1)
Exercise of stock options					10,201			10,201
Comprehensive income/(loss)						7,564	(20,837)	(13,273)
Repurchase and retirement of common stock (shares)			(771)
Repurchase and retirement of common stock			$ (1)				(30,804)	(30,805)
Total equity, end of period at Jun. 30, 2020			$ 75	$ 22	387,611	1,298	947,909	1,336,915
Shares, Outstanding, Ending Balance at Jun. 30, 2020			75,327	22,430
Shares, Outstanding, Beginning Balance at Dec. 31, 2020			77,284	22,430
Total equity, beginning of period at Dec. 31, 2020			$ 77	$ 22	457,161	3,955	1,045,082	1,506,297
Stock-based compensation					7,883			7,883
Grants of restricted stock units					163			163
Exercise of stock options (shares)			303
Exercise of stock options			$ 1		9,100			9,101
Comprehensive income/(loss)						(5,779)	45,329	39,550
Total equity, end of period at Mar. 31, 2021			$ 78	$ 22	474,307	(1,824)	1,090,411	1,562,994
Shares, Outstanding, Ending Balance at Mar. 31, 2021			77,587	22,430
Shares, Outstanding, Beginning Balance at Dec. 31, 2020			77,284	22,430
Total equity, beginning of period at Dec. 31, 2020			$ 77	$ 22	457,161	3,955	1,045,082	$ 1,506,297
Exercise of stock options (shares)								1,019
Comprehensive income/(loss)								$ 81,347
Total equity, end of period at Jun. 30, 2021			$ 79	$ 22	508,788	(1,572)	1,131,956	1,639,273
Shares, Outstanding, Ending Balance at Jun. 30, 2021			78,303	22,430
Shares, Outstanding, Beginning Balance at Mar. 31, 2021			77,587	22,430
Total equity, beginning of period at Mar. 31, 2021			$ 78	$ 22	474,307	(1,824)	1,090,411	1,562,994
Stock-based compensation					7,788			7,788
Grants of restricted stock units					197			197
Exercise of stock options (shares)			716
Exercise of stock options			$ 1		26,496			26,497
Comprehensive income/(loss)						252	41,545	41,797
Total equity, end of period at Jun. 30, 2021			$ 79	$ 22	$ 508,788	$ (1,572)	$ 1,131,956	$ 1,639,273
Shares, Outstanding, Ending Balance at Jun. 30, 2021			78,303	22,430

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net income	$ 86,874	$ 5,112
Adjustments to reconcile net income to net cash provided by operating activities:
Acquired in-process research and development		24,418
Depreciation and amortization	36,287	29,669
Amortization of premium (discount) on marketable securities	1,131	104
Write-down of excess and obsolete inventories	5,000	7,216
Stock-based compensation expense	15,330	14,118
Allowance for doubtful accounts	590	2,455
Change in fair value of business acquisition liabilities	14,128	463
Change in deferred income taxes	(1,783)	(1,127)
(Gain)/loss on disposal of assets, net	191	625
(Increase)/decrease in:
Accounts receivable	(25,587)	19,306
Inventories	(6,024)	(34,371)
Prepaid expenses and other assets	845	(2,875)
Increase/(decrease) in:
Accounts payable	2,737	2,974
Accrued expenses and other liabilities	3,559	(7,756)
Income taxes payable/receivable	(10,519)	5,030
Net cash provided by operating activities	122,759	65,361
Cash flows from investing activities:
Purchases of marketable securities	(293,092)	(57,418)
Maturities of marketable securities	131,739	88,383
Sales of marketable securities	58,154	17,405
Purchases of property and equipment	(22,058)	(32,270)
Acquisition of businesses, net of cash acquired, and purchases of intangible and other assets		(21,991)
Net cash used in investing activities	(125,257)	(5,891)
Cash flows from financing activities:
Payment of business acquisition related liabilities	(3,105)	(853)
Proceeds from exercise of stock options	35,597	15,964
Repurchase of common stock		(104,669)
Net cash provided by/used in financing activities	32,492	(89,558)
Effect of foreign exchange rates on cash	(608)	(82)
Net increase in cash, cash equivalents, and restricted cash	29,386	(30,170)
Cash, cash equivalents, and restricted cash at beginning of period	239,397	195,724
Cash, cash equivalents, and restricted cash at end of period	268,783	165,554
Supplemental disclosures of cash flow information:
Income taxes paid	31,597	2,147
Purchases of property and equipment included in accounts payable and accrued expenses	$ 3,537	$ 6,155

BACKGROUND

BACKGROUND	6 Months Ended
	Jun. 30, 2021
BACKGROUND [Abstract]
Background	NOTE 1. BACKGROUND (a) The Company Globus Medical, Inc., together with its subsidiaries, is a medical device company that develops and commercializes healthcare solutions with a mission to improve the quality of life of patients with musculoskeletal disorders. We are primarily focused on implants that promote healing in patients with musculoskeletal disorders, including the use of a robotic guidance and navigation system and products to treat patients who have experienced orthopedic traumas. We are an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures to assist surgeons in effectively treating their patients and to address new treatment options. With over 220 product launches to date, we offer a comprehensive portfolio of innovative and differentiated technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. We are headquartered in Audubon, Pennsylvania, and we market and sell our products through our exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. Our sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors. The terms the “Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries. (b) COVID-19 Pandemic Impact In March 2020, the World Health Organization declared the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has significantly impacted the economic conditions in the U.S. and globally as federal, state and local governments react to the public health crisis, creating significant uncertainties in the economy. Although the Company cannot reasonably estimate the length or severity of the impact that COVID-19 will have on its financial results, the Company may experience a material adverse impact on its sales, results of operations, and cash flows in 2021 should there be a resurgence impacting hospitals and surgical facilities to which we provide services. In response to these developments, the Company will continue to monitor liquidity and cash flow. The Company has the ability to borrow from its existing credit facility, if needed, although we do not expect to do so due to our cash, cash equivalents and short-term marketable securities balances.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Summary Of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, these condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position as of June 30, 2021, and results of operations for the three and six months ended June 30, 2021. The results of operations for any interim period may not be indicative of results for the full year. (b) Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. (c) Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results. (d) Revenue Recognition Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. For purposes of disclosure, we disaggregate our revenue into two categories, Musculoskeletal Solutions and Enabling Technologies. Our Musculoskeletal Solutions products consist primarily of the implantable devices, disposables, and unique instruments used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of contracts with our customers for Musculoskeletal Solutions products have a single performance obligation and revenue is recognized at a point in time. Our Enabling Technologies products are advanced robotics hardware systems and related technologies that are designed to enhance a surgeon’s capabilities and streamline surgical procedures by making them less invasive, more accurate, and more reproducible to improve patient care. The majority of contracts with our customers for Enabling Technologies products contain multiple performance obligations, including maintenance and support, and revenue is recognized as we fulfill each performance obligation. When contracts have multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold. Nature of Products and Services A significant portion of our Musculoskeletal Solutions product revenue is generated from consigned inventory maintained at hospitals or with sales representatives. Revenue from the sale of consigned musculoskeletal products is recognized when we transfer control, which generally occurs at the time the product is used or implanted. For all other Musculoskeletal Solutions product transactions, we recognize revenue when we transfer title to the goods, provided there are no remaining performance obligations that can affect the customer’s final acceptance of the sale. Revenue from the sale of Enabling Technologies products is generally recognized when control transfers to the customer which occurs at the time the product is shipped or delivered. Any revenue related to the provision of maintenance and support is recognized as we satisfy the performance obligation. We use an observable price to determine the stand-alone selling price for each separate performance obligation. Contract Balances Timing of revenue recognition may differ from the timing of invoicing to customers. We record a receivable when revenue is recognized prior to invoicing, or deferred revenue when revenue is recognized subsequent to invoicing. Deferred revenue is comprised mainly of unearned revenue related to the sales of certain Enabling Technologies products, which includes maintenance and support services. Maintenance and support services are generally invoiced annually, at the beginning of each contract period, and revenue is recognized ratably over the maintenance period. For the three and six months ended June 30, 2021, there was an immaterial amount of revenue recognized from previously deferred revenue. (e) Cash, Cash Equivalents, and Restricted Cash The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, commercial paper and corporate debt securities are stated at fair value. (f) Marketable Securities Our marketable securities include municipal bonds, corporate debt securities, commercial paper, asset-backed securities, and securities of government, federal agency, and other sovereign obligations are classified as available-for-sale as of June 30, 2021. S hort-term and long-term marketable securities are recorded at fair value on our condensed consolidated balance sheets. Any changes in the fair value of our available-for-sale securities, that do not result in recognition or reversal of an allowance for credit loss or write-down, are recorded, net of taxes, as a component of accumulated other comprehensive income or loss on our condensed consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of marketable securities are determined on a specific identification basis. Realized gains and losses, interest income and the amortization/accretion of premiums/discounts are included in other income/(expense), net, on our condensed consolidated statements of operations and comprehensive income. Interest receivable is recorded in prepaid expenses and other current assets on our condensed consolidated balance sheets. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is expected, the loss will be recognized on an allowance basis, consistent with ASC 326-30, in our condensed consolidated statement of operations and comprehensive income in the period the determination is made. (g) Fair Value Measurements Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques. Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value. Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to business acquisitions and is measured at fair value, based on significant inputs that are not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these assumptions on an ongoing basis as additional data impacting the assumptions is obtained. The fair value of contingent consideration recorded in business acquisition liabilities on our condensed consolidated balance sheets, and changes in the fair value of contingent consideration are recognized within acquisition related costs in the condensed consolidated statements of operations and comprehensive income. The fair value of contingent restricted stock unit (“RSU”) grants are recorded as additional paid-in capital in the consolidated balance sheet on the day of the grant due to the remote likelihood of forfeiture. (h) Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The majority of our inventory is finished goods and we utilize both in-house manufacturing and third-party suppliers to produce our products. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a write-down for such excess inventories. Once inventory has been written down, it creates a new cost basis for inventory that is not subsequently written up. (i) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair values of the identifiable assets acquired less the liabilities assumed in the acquisition of a business. Goodwill is tested for impairment at least annually or whenever events or circumstances indicate that a carrying amount may not be recoverable. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. Fair values are estimated using an income and discounted cash flow approach. We perform our annual impairment test of goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. During the six months ended June 30, 2021 and 2020, we did no t record any impairment charges related to goodwill. Intangible assets consist of purchased in-process research and development (“IPR&D”), developed technology, supplier network, patents, customer relationships, re-acquired rights, and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to sixteen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If an impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis. There were no impairments of finite-lived intangible assets during the six months ended June 30, 2021 or 2020. IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. There were no impairments of IPR&D during the six months ended June 30, 2021 or 2020. (j) Stock -Based Compensation The cost of employee and non-employee director awards is measured at the grant date fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the equity award. Compensation expense for awards includes the impact of forfeiture in the period when they occur. We estimate the fair value of stock options utilizing the Black-Scholes option-pricing model. Inputs to the Black-Scholes model include our stock price, expected volatility, expected term, risk-free interest rate and expected dividends. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts. The fair value of restricted stock units is estimated using the closing price of the Company’s common stock on the date of grant. (k) Recently Issued Accounting Pronouncements On March 12, 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is effective for all entities as of March 12, 2020, and will apply through December 31, 2022. To date, we have had no impacts on our investment portfolio or our credit agreement with Citizens Bank, N.A. related to reference rate reform. We will continue to evaluate the impact this guidance could have on our condensed consolidated financial statements and related disclosures. (l) Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”) , which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. We adopted ASU 2019-12 on January 1, 2021. This standard did not have a material impact on our financial position, results of operations and disclosures.

ASSET ACQUISITIONS AND BUSINESS

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS	6 Months Ended
	Jun. 30, 2021
ASSET ACQUISITIONS AND BUSINESS COMBINATIONS [Abstract]
Asset Acquisitions And Business Combinations	NOTE 3. ASSET ACQUISITIONS AND BUSINESS COMBINATIONS Asset Acquisitions During the second quarter of 2020, the Company acquired Synoste Oy (“Synoste”), a Finnish engineering company that specializes in the research and development of a limb lengthening system. The fair value of the net assets acquired was $ 25.3 million, and the consideration consisted of approximately $ 22.8 million of cash paid at closing plus $ 2.5 million of a contractual holdback obligation payable eighteen months from the closing date of the transaction, subject to net working capital and other post-closing adjustments, if applicable. The contractual holdback obligation is included in accrued expenses in the condensed consolidated balance sheet. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset, IPR&D of the limb lengthening system, thus satisfying the requirements of the screen test in ASU 2017-1. At the date of acquisition, the Company determined that the development of the projects underway at Synoste had not yet reached technological feasibility and that the research in process had no alternative future use. Accordingly, the acquired IPR&D of $ 24.4 million was charged to research and development expense in the condensed consolidated statements of operations and comprehensive income at the date of acquisition. The transaction also provides for additional consideration contingent upon the developed product obtaining approval from the U.S. Food and Drug Administration (the “FDA”) of $ 8.0 million within the third anniversary, or $ 4.0 million within the fourth anniversary of the acquisition closing date, respectively. Contingent consideration is not recorded in an asset acquisition until the milestone is met. Business Combinations During the fourth quarter of 2020, the Company completed two acquisitions that were not considered material, individually or collectively, to the condensed consolidated financial statements during the periods presented. These acquisitions have been included in the condensed consolidated financial statements from the date of acquisition. The combined purchase price consisted of approximately $ 1.5 million of cash paid at closing, plus $ 0.3 million of other liabilities and $ 33.2 million of contingent consideration payments. The contingent payments are based upon achieving various performance obligations over a period of 10 years, and are payable in a combination of cash and RSUs. The Company recorded other intangible assets of $ 8.8 million, with a weighted average useful life of 4.2 years, and goodwill of $ 26.2 million based on their preliminary estimated fair values. The purchase price allocation of the assets and liabilities acquired remains open with respect to the final determination of deferred tax asset values. The Company expects the purchase price allocation to be finalized within one year from the date of acquisition. While the Company does not expect material changes from the initial outcome of the valuation, certain assumptions and findings made at the date of acquisition could result in changes in the purchase price allocation. During the second quarter of 2019, the Company acquired substantially all of the assets of StelKast, Inc. (the “StelKast Acquisition”), a privately held company that designs, manufactures and distributes orthopedic implants for knee and hip replacement surgeries. The Company has included the financial results from the StelKast Acquisition in our condensed consolidated financial statements from the acquisition date. At the acquisition date, the fair value of the net assets acquired was $ 28.1 million. The purchase price consisted of approximately $ 23.8 million of cash paid at closing, plus $ 4.3 million of contingent consideration payable based upon the achievement of product sales milestones. The Company recorded identifiable net assets, based on their estimated fair values, for inventory of $ 15.3 million, fixed assets of $ 4.2 million and customer relationships of $ 3.9 million and goodwill of $ 4.7 million. The contingent consideration payable related to the StelKast Acquisition of $ 5.0 million was paid during the third quarter of 2020.

NET SALES

NET SALES	6 Months Ended
	Jun. 30, 2021
NET SALES [Abstract]
Net Sales	NOTE 4. NET SALES The following table represents net sales by product category: Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Musculoskeletal Solutions $ 230,263 $ 143,480 $ 442,679 $ 326,022 Enabling Technologies 20,753 5,442 35,681 13,477 Total net sales $ 251,016 $ 148,922 $ 478,360 $ 339,499

MARKETABLE SECURITIES

MARKETABLE SECURITIES	6 Months Ended
	Jun. 30, 2021
MARKETABLE SECURITIES [Abstract]
Marketable Securities	NOTE 5. MARKETABLE SECURITIES The composition of our short-term and long-term marketable securities was as follows: June 30, 2021 (In thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term: Municipal bonds $ 43,165 $ 290 $ ( 6 ) $ 43,449 Corporate debt securities 93,091 1,088 — 94,179 Commercial paper 34,504 6 — 34,510 Asset-backed securities 16,016 89 — 16,105 Government, federal agency, and other sovereign obligations 3,400 1 — 3,401 Total short-term marketable securities $ 190,176 $ 1,474 $ ( 6 ) $ 191,644 Long-term: Municipal bonds $ 77,142 $ 168 $ ( 48 ) $ 77,262 Corporate debt securities 220,562 1,257 ( 77 ) 221,742 Asset-backed securities 154,138 695 ( 111 ) 154,722 Total long-term marketable securities $ 451,842 $ 2,120 $ ( 236 ) $ 453,726 December 31, 2020 (In thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term: Municipal bonds $ 39,684 $ 140 $ — $ 39,824 Corporate debt securities 97,937 817 ( 4 ) 98,750 Commercial paper 25,543 4 — 25,547 Asset-backed securities 15,232 44 — 15,276 Government, federal agency, and other sovereign obligations 7,886 61 — 7,947 Total short-term marketable securities $ 186,282 $ 1,066 $ ( 4 ) $ 187,344 Long-term: Municipal bonds $ 70,176 $ 612 $ — $ 70,788 Corporate debt securities 158,464 3,120 — 161,584 Asset-backed securities 124,406 1,747 ( 3 ) 126,150 Total long-term marketable securities $ 353,046 $ 5,479 $ ( 3 ) $ 358,522 The short-term marketable securities have effective maturity dates of less than one year and the long-term marketable securities have effective maturity dates ranging from one to three years as of June 30, 2021 and December 31, 2020, respectively. Purchases of marketable securities include amounts payable to brokers of $ 9.7 million and $ 9.3 million as of June 30, 2021 and December 31, 2020, respectively.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2021
FAIR VALUE MEASUREMENTS [Abstract]
Fair Value Measurements	NOTE 6. FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis included the following: (In thousands) Balance at June 30, 2021 Level 1 Level 2 Level 3 Assets: Cash equivalents $ 29,147 $ 25,473 $ 3,674 $ — Municipal bonds 120,711 — 120,711 — Corporate debt securities 315,921 — 315,921 — Commercial paper 34,510 — 34,510 — Asset-backed securities 170,827 — 170,827 — Government, federal agency, and other sovereign obligations 3,401 — 3,401 — Liabilities: Business acquisition liabilities 47,995 — — 47,995 (In thousands) Balance at December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash equivalents $ 56,223 $ 23,628 $ 32,595 $ — Municipal bonds 110,612 — 110,612 — Corporate debt securities 260,334 — 260,334 — Commercial paper 25,547 — 25,547 — Asset-backed securities 141,426 — 141,426 — Government, federal agency, and other sovereign obligations 7,947 — 7,947 — Liabilities: Business acquisition liabilities 37,270 — — 37,270 Our marketable securities are classified as Level 2 within the fair value hierarchy, as we measure their fair value using market prices for similar instruments and inputs such as actual trade data, benchmark yields, broker/dealer quotes and other similar data obtained from quoted market prices or independent pricing vendors. Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis Fair value of the revenue-based business acquisition liabilities was determined using a discounted cash flow model and an option pricing model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility and discount rates, market price risk adjustment, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The following are the significant unobservable inputs used in the two valuation techniques: Unobservable input Range Weighted Average* Revenue risk premium 3.0 % - 4.9 % 3.3 % Revenue volatility 14.0 % - 15.8 % 14.3 % Discount rate 1.2 % - 8.5 % 3.4 % Projected year of payment 2021 - 2030 * The weighted average rates were calculated based on the relative fair value of each business acquisition liability. The change in the carrying value of the business acquisition liabilities during the three and six months ended June 30, 2021 and 2020, respectively included the following: Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Fair value measurement at beginning of period $ 36,020 $ 9,489 $ 37,270 $ 9,549 Contingent cash payments ( 1,523 ) ( 287 ) ( 3,015 ) ( 853 ) Contingent RSU grants ( 197 ) — ( 360 ) — Changes in fair value of business acquisition liabilities 13,870 ( 43 ) 14,128 463 Contractual payable reclassification ( 175 ) ( 4,943 ) ( 28 ) ( 4,943 ) Fair value measurement at June 30, 2021 and 2020, respectively $ 47,995 $ 4,216 $ 47,995 $ 4,216 Changes in the fair value of business acquisition liabilities are driven by changes in market conditions and the achievement of certain performance conditions.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2021
INVENTORIES [Abstract]
Inventories	NOTE 7. INVENTORIES Inventories included the following: June 30, December 31, (In thousands) 2021 2020 Raw materials $ 42,080 $ 39,646 Work in process 16,771 16,446 Finished goods 172,357 173,061 Total inventories $ 231,208 $ 229,153 During the three months ended June 30, 2021 and 2020, net adjustments to cost of sales related to excess and obsolete inventory were $ 3.4 million and $ 6.5 million, respectively. The net adjustments for the three months ended June 30, 2021 and 2020 reflect a combination of additional expense for excess and obsolete related provisions ($ 7.6 million and $ 8.5 million, respectively) offset by sales and disposals ($ 4.2 million and $ 2.0 million, respectively) of inventory for which an excess and obsolete provision was provided previously through expense recognized in prior periods. During the six months ended June 30, 2021 and 2020, net adjustments to cost of sales related to excess and obsolete inventory were $ 5.0 million and $ 7.2 million, respectively. The net adjustments for the six months ended June 30, 2021 and 2020 reflect a combination of additional expense for excess and obsolete related provisions ($ 11.4 million and $ 10.9 million, respectively) offset by sales and disposals ($ 6.4 million and $ 3.7 million, respectively) of inventory for which an excess and obsolete provision was provided previously through expense recognized in prior periods.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Jun. 30, 2021
PROPERTY AND EQUIPMENT [Abstract]
PROPERTY AND EQUIPMENT	NOTE 8. PROPERTY AND EQUIPMENT Property and equipment included the following: Useful June 30, December 31, (In thousands) Life 2021 2020 Land — $ 8,314 $ 8,322 Buildings and improvements 31.5 44,420 33,825 Equipment 5 - 15 109,557 102,553 Instruments 5 282,245 278,930 Modules and cases 5 42,772 41,919 Other property and equipment 3 - 5 16,975 27,781 504,283 493,330 Less: accumulated depreciation ( 293,534 ) ( 276,451 ) Total $ 210,749 $ 216,879 Instruments are hand-held devices used by surgeons to install implants during surgery. Modules and cases are used to store and transport the instruments and implants. Depreciation expense related to property and equipment was as follows: Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Depreciation $ 14,506 $ 10,987 $ 26,890 $ 21,778

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2021
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Goodwill and Intangible Assets	NOTE 9. GOODWILL AND INTANGIBLE ASSETS The change in the carrying amount of goodwill during the twelve months ended December 31, 2020 and the six months ended June 30, 2021, respectively included the following: (In thousands) December 31, 2019 $ 128,775 Additions and adjustments 26,043 Foreign exchange 1,898 December 31, 2020 156,716 Foreign exchange ( 939 ) June 30, 2021 $ 155,777 The composition of intangible assets was as follows: June 30, 2021 (In thousands) Weighted Average Amortization Period (in years) Gross Carrying Amount Accumulated Amortization Intangible Assets, net Supplier network 10.0 $ 4,000 $ ( 2,667 ) $ 1,333 Customer relationships & other intangibles 6.5 55,427 ( 34,751 ) 20,676 Developed technology 8.0 71,987 ( 23,853 ) 48,134 Patents 16.1 8,946 ( 2,936 ) 6,010 Total intangible assets $ 140,360 $ ( 64,207 ) $ 76,153 December 31, 2020 (In thousands) Weighted Average Amortization Period (in years) Gross Carrying Amount Accumulated Amortization Intangible Assets, net Supplier network 10.0 $ 4,000 $ ( 2,467 ) $ 1,533 Customer relationships & other intangibles 6.5 57,704 ( 32,056 ) 25,648 Developed technology 8.0 72,644 ( 19,295 ) 53,349 Patents 16.1 9,082 ( 2,663 ) 6,419 Total intangible assets $ 143,430 $ ( 56,481 ) $ 86,949 The following table summarizes amortization of intangible assets for future periods as of June 30, 2021: (In thousands) Annual Amortization Remaining 2021 $ 9,067 2022 17,816 2023 15,723 2024 12,744 2025 8,715 Thereafter 12,088 Total $ 76,153

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2021
ACCRUED EXPENSES [Abstract]
Accrued Expenses	NOTE 10. ACCRUED EXPENSES Accrued expense included the following: June 30, December 31, (In thousands) 2021 2020 Compensation and other employee-related costs $ 44,692 $ 44,948 Legal and other settlements and expenses 763 650 Accrued non-income taxes 5,473 4,952 Royalties 4,270 3,720 Other 23,255 24,064 Total accrued expenses $ 78,453 $ 78,334

DEBT

DEBT	6 Months Ended
	Jun. 30, 2021
DEBT [Abstract]
Debt	NOTE 11. DEBT Line of Credit In August 2020, we entered into a credit agreement with Citizens Bank, N.A. (the “Credit Agreement”) that provides a revolving credit facility permitting borrowings up to $ 125.0 million (the “Revolving Credit Facility”). As amended, the Credit Agreement has a termination date of August 3, 2022 . The Revolving Credit Facility includes up to a $ 25.0 million sub limit for letters of credit. Revolving loans under the Credit Agreement will bear interest, at the Company’s option, at either a base rate or the Adjusted LIBOR Rate (as defined in the Credit Agreement), plus, in each case, an applicable margin, as determined in accordance with the provisions of the Credit Agreement. The base rate will be the highest of: the rate of interest announced publicly by Citizens Bank, N.A. from time to time as its “prime rate”; the federal funds effective rate plus 1/2 of 1 %; and the Adjusted LIBOR Rate for a one-month period plus 1 %. The applicable margin is subject to adjustment as provided in the Credit Agreement. The Credit Agreement contains financial and other customary covenants, including a maximum leverage ratio. As of June 30, 2021, we have no t borrowed under the Credit Agreement with Citizens Bank, N.A.

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2021
EQUITY [Abstract]
Equity	NOTE 12. EQUITY Stock Repurchases Under the current stock repurchase plan, announced in March 2020, the Company is authorized to repurchase up to $ 200 million of the Company’s Class A common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. As of June 30, 2021, $ 95.3 million of this authorization is remaining. The timing and actual number of shares repurchased will depend on various factors including price, corporate and regulatory requirements, debt covenant requirements, alternative investment opportunities and other market conditions. F unding of share repurchases is expected to come from operating cash flows and excess cash. Shares repurchased by the Company are accounted for under the constructive retirement method, in which the shares repurchased, are immediately retired, as there is no plan to reissue. The Company made an accounting policy election to charge the excess of repurchase price over par value entirely to retained earnings. The following table summarizes the activity related to share repurchases: (In thousands except for per share prices) Period Total number of shares repurchased Average Price Paid per Share Dollar amount of shares repurchased (1) Approximate dollar value of shares that may yet be purchased under the plan January 1, 2020 - March 31, 2020 1,920 $ 38.49 $ 73,902 $ 126,098 April 1, 2020 - June 30, 2020 771 39.95 30,804 95,294 July 1, 2020 - September 30,2020 — — — 95,294 October 1, 2020 - December 31, 2020 — — — 95,294 January 1, 2021 - March 31, 2021 — — — 95,294 April 1, 2021 - June 30, 2021 — — — $ 95,294 January 1, 2020 - June 30, 2021 2,691 $ 38.91 $ 104,706 (1) Inclusive of an immaterial amount of commission fees Common Stock Our amended and restated Certificate of Incorporation provides for a total of 775,000,000 authorized shares of common stock. Of the authorized number of shares of common stock, 500,000,000 shares are designated as Class A common stock (“Class A Common”), and 275,000,000 shares are designated as Class B common stock (“Class B Common”). The holders of Class A Common are entitled to one vote for each share of Class A Common held. The holders of Class B Common are entitled to 10 votes for each share of Class B Common held. The holders of Class A Common and Class B Common vote together as one class of common stock on all matters submitted to a vote of stockholders, except as required by law or our amended and restated Certificate of Incorporation. Each share of our Class B common stock is convertible at any time at the option of the holder into one share of our Class A common stock. In addition, each share of our Class B common stock will convert automatically into one share of our Class A common stock upon any transfer, whether or not for value, except for permitted transfers. For more details relating to the conversion of our Class B common stock please see “Exhibit 4.2, Description of Securities of the Registrant” filed with our Annual Report on Form 10-K on February 17, 2021. Accumulated Other Comprehensive Income (Loss) The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss) for the six months ended June 30, 2021 and 2020, respectively: (In thousands) Unrealized gain/(loss) on marketable securities, net of tax Foreign currency translation adjustments Accumulated other comprehensive loss Accumulated other comprehensive loss, net of tax, at December 31, 2020 $ 5,001 $ ( 1,046 ) $ 3,955 Other comprehensive (loss)/income before reclassifications ( 3,188 ) ( 3,087 ) ( 6,275 ) Amounts reclassified from accumulated other comprehensive income, net of tax 748 — 748 Other comprehensive (loss)/income, net of tax ( 2,440 ) ( 3,087 ) ( 5,527 ) Accumulated other comprehensive loss, net of tax, at June 30, 2021 $ 2,561 $ ( 4,133 ) $ ( 1,572 ) (In thousands) Unrealized gain/(loss) on marketable securities, net of tax Foreign currency translation adjustments Accumulated other comprehensive loss Accumulated other comprehensive loss, net of tax, at December 31, 2019 $ 3,599 $ ( 6,497 ) $ ( 2,898 ) Other comprehensive (loss)/income before reclassifications 4,004 1,141 5,145 Amounts reclassified from accumulated other comprehensive income, net of tax ( 949 ) — ( 949 ) Other comprehensive (loss)/income, net of tax 3,055 1,141 4,196 Accumulated other comprehensive loss, net of tax, at June 30, 2020 $ 6,654 $ ( 5,356 ) $ 1,298 Amounts reclassified from accumulated other comprehensive loss, net of tax, related to unrealized gains/losses on marketable securities were released to other income, net in our condensed consolidated statements of operations and comprehensive income. Earnings Per Common Share The Company computes basic earnings per share using the weighted-average number of common shares outstanding during the period. Diluted earnings per share assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would be anti-dilutive. For purposes of this calculation, common stock equivalents include the Company’s stock options and unvested RSUs. The contingently issuable shares are included in basic net income per share as of the date that all necessary conditions have been satisfied and are included in the denominator for dilutive calculation for the entire period if such shares would be issuable as of the end of the reporting period assuming the end of the reporting period was the end of the contingency period. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2021 2020 2021 2020 Numerator: Net income/(loss) $ 41,545 $ ( 20,837 ) $ 86,874 $ 5,112 Denominator for basic and diluted net income per share: Weighted average shares outstanding for basic 100,449 97,509 100,159 98,572 Dilutive stock options and RSUs 3,026 — 2,772 2,420 Weighted average shares outstanding for diluted 103,475 97,509 102,931 100,992 Earnings per share: Basic $ 0.41 $ ( 0.21 ) $ 0.87 $ 0.05 Diluted $ 0.40 $ ( 0.21 ) $ 0.84 $ 0.05 Anti-dilutive stock options and RSUs excluded from the calculation 1,680 11,680 2,372 6,645

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2021
STOCK-BASED COMPENSATION [Abstract]
Stock-Based Compensation	NOTE 13. STOCK-BASED COMPENSATION We have three stock plans: our 2008 Stock Plan, our 2012 Equity Incentive Plan (the “2012 Plan”), and our 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan is the only active stock plan. The purpose of the 2008 and 2012 Stock Plans was, and of the 2021 Plan is, to provide incentive to employees, directors, and consultants of Globus. The Plans are administered by the Board of Directors of Globus (the “Board”) or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, which is generally not more than ten years from the grant date. Options granted to employees generally vest in varying installments over a four-year period. The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common stock that were able to be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3 % of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that were able to be issued or transferred pursuant to incentive stock options under the 2012 Plan was limited to 10,769,230 shares. The shares of Class A Common stock covered by the 2012 Plan included authorized but unissued shares, treasury shares or shares of common stock purchased on the open market. The 2021 Plan was approved by our Board in March 2021, and by our stockholders in June 2021. Under the 2021 Plan, the aggregate number of shares of Class A Common stock that were able to be issued subject to options and other awards is equal to the sum of (i) 2,000,000 shares, (ii) any shares available for issuance under the 2012 Plan as of June 3, 2021 and (iii) any shares underlying awards outstanding under the 2012 Plan or 2021 Plan as of June 3, 2021 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2021 Plan is limited to 2,000,000 shares. The shares of Class A Common stock covered by the 2021 Plan include authorized but unissued shares, treasury shares or shares of common stock purchased on the open market. As of June 30, 2021, pursuant to the 2021 Plan, there were 2,845,575 shares of Class A Common stock reserved and 2,791,397 shares of Class A Common stock available for future grants. Stock Options Stock option activity during the six months ended June 30, 2021 is summarized as follows: Option Shares (thousands) Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value (thousands) Outstanding at December 31, 2020 9,746 $ 41.33 Granted 1,662 65.48 Exercised ( 1,019 ) 34.97 Forfeited ( 349 ) 50.53 Outstanding at June 30, 2021 10,040 $ 45.65 7.3 $ 320,001 Exercisable at June 30, 2021 4,767 $ 37.08 6.1 $ 192,821 Expected to vest at June 30, 2021 5,273 $ 53.41 8.4 $ 127,180 The total intrinsic value of stock options exercised was $ 25.0 million and $ 12.7 million during the three months ended June 30, 2021, and 2020, respectively. The total intrinsic value of stock options exercised was $ 35.1 million and $ 16.2 million during the six months ended June 30, 2021, and 2020, respectively. The fair value of the options was estimated on the date of the grant using a Black-Scholes option pricing model with the following assumptions: Six Months Ended June 30, 2021 2020 Risk-free interest rate 0.40 % - 0.84 % 0.32 % - 1.67 % Expected term (years) 4.8 4.9 Expected volatility 34.0 % 28.0 % - 33.0 % Expected dividend yield —% —% The weighted average grant date fair value of stock options granted during the three months ended June 30, 2021, and 2020 was $ 21.30 and $ 12.42 per share, respectively. The weighted average grant date fair value of stock options granted during the six months ended June 30, 2021, and 2020 was $ 19.58 and $ 14.29 per share, respectively. Restricted Stock Units Restricted stock unit activity during the six months ended June 30, 2021 is summarized as follows: Restricted Stock Units (thousands) Weighted average grant date fair value per share Weighted average remaining contractual life (years) Outstanding at December 31, 2020 3 $ 58.69 Granted 5 67.83 Vested — — Forfeited — — Outstanding at June 30, 2021 8 $ 64.36 9.3 Stock-Based Compensation Compensation expense related to stock options granted to employees and non-employees under the Plans was as follows: Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Stock-based compensation expense $ 7,632 $ 7,311 $ 15,330 $ 14,118 Net stock-based compensation capitalized into inventory 156 115 341 210 Total stock-based compensation cost $ 7,788 $ 7,426 $ 15,671 $ 14,328 As of June 30, 2021, there was $ 70.0 million of unrecognized compensation expense related to unvested employee stock options that are expected to vest over a weighted average period of approximately three years .

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2021
INCOME TAXES [Abstract]
Income Taxes	NOTE 14. INCOME TAXES In computing our income tax provision, we make certain estimates and judgments, such as estimated annual taxable income or loss, annual effective tax rate, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. Our estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. Should facts and circumstances change during a quarter causing a material change to the estimated effective income tax rate, a cumulative adjustment is recorded. The following table provides a summary of our effective tax rate for the three and six months ended June 30, 2021 and 2020, respectively: Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Effective income tax rate 15.1 % 5.0 % 18.1 % 51.6 % The change in the effective income tax rates for the three and six month periods ending June 30, 2021 and 2020 is primarily driven by the increase in pretax income and impact of the non-tax-deductible expense of acquired IPR&D of $ 24.4 million for the three and six month periods ending June 30, 2020, which were partially offset by tax benefits due to an increase in stock option exercises in the current year.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
COMMITMENTS AND CONTINGENCIES [Abstract]
Commitments and Contingencies	NOTE 15. COMMITMENTS AND CONTINGENCIES We are involved in a number of proceedings, legal actions, and claims arising in the ordinary course of business. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the condensed consolidated financial statements for these actions when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount in the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not probable, and the amount can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows. Moskowitz Family LLC Litigation On November 20, 2019, Moskowitz Family LLC filed suit against us in the U.S. District Court for the Western District of Texas for patent infringement. Moskowitz, a non-practicing entity, alleges that Globus willfully infringes one or more claims of eight patents by making, using, offering for sale or selling the COALITION ® , COALITION MIS ® , COALITION AGX ® , CORBEL TM , MONUMENT ® , MAGNIFY ® -S, HEDRON IA TM , HEDRON IC TM , INDEPENDENCE ® , INDEPENDENCE MIS ® , INDEPENDENCE MIS AGX ® , FORTIFY ® and XPAND ® families, SABLE TM , RISE ® , RISE ® INTRALIF, RISE ® -L, ELSA ® , ELSA ® ATP, RASS, ALTERA ® , ARIEL ® , LATIS ® , CALIBER ® and CALIBER ® -L products. Moskowitz seeks an unspecified amount in damages and injunctive relief. On July 2, 2020, this suit was transferred from the U.S. District Court for the Western District of Texas to the U.S. District Court for the Eastern District of Pennsylvania. The outcome of this litigation cannot be determined, nor can we estimate a range of potential loss, therefore, we have no t recorded a liability related to this litigation as of June 30, 2021.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
LEASES [Abstract]
Leases	NOTE 16. LEASES The Company leases certain equipment, vehicles, and facilities under the terms of operating lease agreements. Our leases have initial lease terms ranging from one year to fourteen years . Certain leases contain options to extend the term beyond the initial lease termination date. We use judgment to determine whether it is reasonably possible that we will extend the lease beyond the initial term and the length of the possible extension. Leases that have terms of less than 12 months are treated as short-term and we do not recognize right of use assets or lease liabilities for such leases. We generally estimate discount rates using our incremental borrowing rate, and based on other information available, at commencement date of a lease when determining the present value of future payments as most of our leases do not provide an implicit rate. The Company includes right-of-use assets in other assets, short-term lease liabilities in accrued expenses, and long-term lease liabilities in other liabilities on the condensed consolidated balance sheet. Lease expense is recognized, on a straight-line basis over the term of the lease, as a component of operating income on the condensed consolidated statement of operations and comprehensive income. Amounts reported in the condensed consolidated balance sheet were as follows: June 30, December 31, (In thousands, except weighted average lease term and discount rate) 2021 2020 Operating lease right of use asset $ 5,821 $ 4,741 Lease liability - current 2,144 1,865 Lease liability - long-term 3,804 2,936 Total operating lease liability $ 5,948 $ 4,801 Supplemental non-cash information: Weighted-average remaining lease term (years) - operating leases 3.2 2.9 Weighted-average discount rate - operating leases 3.3 % 3.0 % Operating lease expense recognized in the condensed consolidated statement of operations and comprehensive income was as follows: Three months ended Six months ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Operating lease expense $ 811 $ 869 $ 1,678 $ 1,748 Future minimum lease payments under non-cancellable leases as of June 30, 2021 are as follows: (In thousands) Operating Leases Remaining 2021 $ 1,172 2022 2,153 2023 1,463 2024 993 2025 399 Thereafter 154 Total undiscounted operating lease payments $ 6,334 Less: imputed interest 386 Total operating lease liability $ 5,948

SEGMENT AND GEOGRAPHIC INFORMAT

SEGMENT AND GEOGRAPHIC INFORMATION	6 Months Ended
	Jun. 30, 2021
SEGMENT AND GEOGRAPHIC INFORMATION [Abstract]
Segment and Geographic Information	NOTE 17. SEGMENT AND GEOGRAPHIC INFORMATION Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We manage our business globally within one operating segment, and segment information is consistent with how the chief operating decision makers review the business, makes investing and resource allocation decisions and assesses operating performance. The following table represents total net sales by geographic area, based on the location of the customer: Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 United States $ 215,119 $ 125,154 $ 408,436 $ 283,601 International 35,897 23,768 69,924 55,898 Total net sales $ 251,016 $ 148,922 $ 478,360 $ 339,499

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	6 Months Ended
	Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, these condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position as of June 30, 2021, and results of operations for the three and six months ended June 30, 2021. The results of operations for any interim period may not be indicative of results for the full year.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Revenue Recognition	Revenue Recognition Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. For purposes of disclosure, we disaggregate our revenue into two categories, Musculoskeletal Solutions and Enabling Technologies. Our Musculoskeletal Solutions products consist primarily of the implantable devices, disposables, and unique instruments used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of contracts with our customers for Musculoskeletal Solutions products have a single performance obligation and revenue is recognized at a point in time. Our Enabling Technologies products are advanced robotics hardware systems and related technologies that are designed to enhance a surgeon’s capabilities and streamline surgical procedures by making them less invasive, more accurate, and more reproducible to improve patient care. The majority of contracts with our customers for Enabling Technologies products contain multiple performance obligations, including maintenance and support, and revenue is recognized as we fulfill each performance obligation. When contracts have multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold. Nature of Products and Services A significant portion of our Musculoskeletal Solutions product revenue is generated from consigned inventory maintained at hospitals or with sales representatives. Revenue from the sale of consigned musculoskeletal products is recognized when we transfer control, which generally occurs at the time the product is used or implanted. For all other Musculoskeletal Solutions product transactions, we recognize revenue when we transfer title to the goods, provided there are no remaining performance obligations that can affect the customer’s final acceptance of the sale. Revenue from the sale of Enabling Technologies products is generally recognized when control transfers to the customer which occurs at the time the product is shipped or delivered. Any revenue related to the provision of maintenance and support is recognized as we satisfy the performance obligation. We use an observable price to determine the stand-alone selling price for each separate performance obligation. Contract Balances Timing of revenue recognition may differ from the timing of invoicing to customers. We record a receivable when revenue is recognized prior to invoicing, or deferred revenue when revenue is recognized subsequent to invoicing. Deferred revenue is comprised mainly of unearned revenue related to the sales of certain Enabling Technologies products, which includes maintenance and support services. Maintenance and support services are generally invoiced annually, at the beginning of each contract period, and revenue is recognized ratably over the maintenance period. For the three and six months ended June 30, 2021, there was an immaterial amount of revenue recognized from previously deferred revenue.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, commercial paper and corporate debt securities are stated at fair value.
Marketable Securities	Marketable Securities Our marketable securities include municipal bonds, corporate debt securities, commercial paper, asset-backed securities, and securities of government, federal agency, and other sovereign obligations are classified as available-for-sale as of June 30, 2021. S hort-term and long-term marketable securities are recorded at fair value on our condensed consolidated balance sheets. Any changes in the fair value of our available-for-sale securities, that do not result in recognition or reversal of an allowance for credit loss or write-down, are recorded, net of taxes, as a component of accumulated other comprehensive income or loss on our condensed consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of marketable securities are determined on a specific identification basis. Realized gains and losses, interest income and the amortization/accretion of premiums/discounts are included in other income/(expense), net, on our condensed consolidated statements of operations and comprehensive income. Interest receivable is recorded in prepaid expenses and other current assets on our condensed consolidated balance sheets. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is expected, the loss will be recognized on an allowance basis, consistent with ASC 326-30, in our condensed consolidated statement of operations and comprehensive income in the period the determination is made.
Fair Value Measurements	Fair Value Measurements Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques. Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value. Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to business acquisitions and is measured at fair value, based on significant inputs that are not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these assumptions on an ongoing basis as additional data impacting the assumptions is obtained. The fair value of contingent consideration recorded in business acquisition liabilities on our condensed consolidated balance sheets, and changes in the fair value of contingent consideration are recognized within acquisition related costs in the condensed consolidated statements of operations and comprehensive income. The fair value of contingent restricted stock unit (“RSU”) grants are recorded as additional paid-in capital in the consolidated balance sheet on the day of the grant due to the remote likelihood of forfeiture.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The majority of our inventory is finished goods and we utilize both in-house manufacturing and third-party suppliers to produce our products. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a write-down for such excess inventories. Once inventory has been written down, it creates a new cost basis for inventory that is not subsequently written up.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair values of the identifiable assets acquired less the liabilities assumed in the acquisition of a business. Goodwill is tested for impairment at least annually or whenever events or circumstances indicate that a carrying amount may not be recoverable. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. Fair values are estimated using an income and discounted cash flow approach. We perform our annual impairment test of goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. During the six months ended June 30, 2021 and 2020, we did no t record any impairment charges related to goodwill. Intangible assets consist of purchased in-process research and development (“IPR&D”), developed technology, supplier network, patents, customer relationships, re-acquired rights, and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to sixteen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If an impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis. There were no impairments of finite-lived intangible assets during the six months ended June 30, 2021 or 2020. IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. There were no impairments of IPR&D during the six months ended June 30, 2021 or 2020.
Stock-Based Compensation	Stock -Based Compensation The cost of employee and non-employee director awards is measured at the grant date fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the equity award. Compensation expense for awards includes the impact of forfeiture in the period when they occur. We estimate the fair value of stock options utilizing the Black-Scholes option-pricing model. Inputs to the Black-Scholes model include our stock price, expected volatility, expected term, risk-free interest rate and expected dividends. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts. The fair value of restricted stock units is estimated using the closing price of the Company’s common stock on the date of grant.
Recently Issued Accounting Pronouncements & Recently Adopted Accounting Pronouncements	Recently Issued Accounting Pronouncements On March 12, 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is effective for all entities as of March 12, 2020, and will apply through December 31, 2022. To date, we have had no impacts on our investment portfolio or our credit agreement with Citizens Bank, N.A. related to reference rate reform. We will continue to evaluate the impact this guidance could have on our condensed consolidated financial statements and related disclosures. (l) Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”) , which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. We adopted ASU 2019-12 on January 1, 2021. This standard did not have a material impact on our financial position, results of operations and disclosures.

NET SALES (Tables)

NET SALES (Tables)	6 Months Ended
	Jun. 30, 2021
NET SALES [Abstract]
Schedule of Net Sales by Product Category	Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Musculoskeletal Solutions $ 230,263 $ 143,480 $ 442,679 $ 326,022 Enabling Technologies 20,753 5,442 35,681 13,477 Total net sales $ 251,016 $ 148,922 $ 478,360 $ 339,499

MARKETABLE SECURITIES (Tables)

MARKETABLE SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2021
MARKETABLE SECURITIES [Abstract]
Composition of Marketable Securities	The composition of our short-term and long-term marketable securities was as follows: June 30, 2021 (In thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term: Municipal bonds $ 43,165 $ 290 $ ( 6 ) $ 43,449 Corporate debt securities 93,091 1,088 — 94,179 Commercial paper 34,504 6 — 34,510 Asset-backed securities 16,016 89 — 16,105 Government, federal agency, and other sovereign obligations 3,400 1 — 3,401 Total short-term marketable securities $ 190,176 $ 1,474 $ ( 6 ) $ 191,644 Long-term: Municipal bonds $ 77,142 $ 168 $ ( 48 ) $ 77,262 Corporate debt securities 220,562 1,257 ( 77 ) 221,742 Asset-backed securities 154,138 695 ( 111 ) 154,722 Total long-term marketable securities $ 451,842 $ 2,120 $ ( 236 ) $ 453,726 December 31, 2020 (In thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term: Municipal bonds $ 39,684 $ 140 $ — $ 39,824 Corporate debt securities 97,937 817 ( 4 ) 98,750 Commercial paper 25,543 4 — 25,547 Asset-backed securities 15,232 44 — 15,276 Government, federal agency, and other sovereign obligations 7,886 61 — 7,947 Total short-term marketable securities $ 186,282 $ 1,066 $ ( 4 ) $ 187,344 Long-term: Municipal bonds $ 70,176 $ 612 $ — $ 70,788 Corporate debt securities 158,464 3,120 — 161,584 Asset-backed securities 124,406 1,747 ( 3 ) 126,150 Total long-term marketable securities $ 353,046 $ 5,479 $ ( 3 ) $ 358,522

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2021
FAIR VALUE MEASUREMENTS [Abstract]
Fair Value of Assets and Liabilities Measured on Recurring Basis	(In thousands) Balance at June 30, 2021 Level 1 Level 2 Level 3 Assets: Cash equivalents $ 29,147 $ 25,473 $ 3,674 $ — Municipal bonds 120,711 — 120,711 — Corporate debt securities 315,921 — 315,921 — Commercial paper 34,510 — 34,510 — Asset-backed securities 170,827 — 170,827 — Government, federal agency, and other sovereign obligations 3,401 — 3,401 — Liabilities: Business acquisition liabilities 47,995 — — 47,995 (In thousands) Balance at December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash equivalents $ 56,223 $ 23,628 $ 32,595 $ — Municipal bonds 110,612 — 110,612 — Corporate debt securities 260,334 — 260,334 — Commercial paper 25,547 — 25,547 — Asset-backed securities 141,426 — 141,426 — Government, federal agency, and other sovereign obligations 7,947 — 7,947 — Liabilities: Business acquisition liabilities 37,270 — — 37,270
Significant Unobservable Inputs in Valuation Techniques	Unobservable input Range Weighted Average* Revenue risk premium 3.0 % - 4.9 % 3.3 % Revenue volatility 14.0 % - 15.8 % 14.3 % Discount rate 1.2 % - 8.5 % 3.4 % Projected year of payment 2021 - 2030 * The weighted average rates were calculated based on the relative fair value of each business acquisition liability.
Changes in Carrying Value of Business Acquisition Liabilities	Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Fair value measurement at beginning of period $ 36,020 $ 9,489 $ 37,270 $ 9,549 Contingent cash payments ( 1,523 ) ( 287 ) ( 3,015 ) ( 853 ) Contingent RSU grants ( 197 ) — ( 360 ) — Changes in fair value of business acquisition liabilities 13,870 ( 43 ) 14,128 463 Contractual payable reclassification ( 175 ) ( 4,943 ) ( 28 ) ( 4,943 ) Fair value measurement at June 30, 2021 and 2020, respectively $ 47,995 $ 4,216 $ 47,995 $ 4,216

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2021
INVENTORIES [Abstract]
Schedule of Inventory	June 30, December 31, (In thousands) 2021 2020 Raw materials $ 42,080 $ 39,646 Work in process 16,771 16,446 Finished goods 172,357 173,061 Total inventories $ 231,208 $ 229,153

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2021
PROPERTY AND EQUIPMENT [Abstract]
Schedule of Property and Equipment	Useful June 30, December 31, (In thousands) Life 2021 2020 Land — $ 8,314 $ 8,322 Buildings and improvements 31.5 44,420 33,825 Equipment 5 - 15 109,557 102,553 Instruments 5 282,245 278,930 Modules and cases 5 42,772 41,919 Other property and equipment 3 - 5 16,975 27,781 504,283 493,330 Less: accumulated depreciation ( 293,534 ) ( 276,451 ) Total $ 210,749 $ 216,879
Schedule of Depreciation Related to Property and Equipment	Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Depreciation $ 14,506 $ 10,987 $ 26,890 $ 21,778

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2021
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Summary of Goodwill	(In thousands) December 31, 2019 $ 128,775 Additions and adjustments 26,043 Foreign exchange 1,898 December 31, 2020 156,716 Foreign exchange ( 939 ) June 30, 2021 $ 155,777
Summary of Intangible Assets	June 30, 2021 (In thousands) Weighted Average Amortization Period (in years) Gross Carrying Amount Accumulated Amortization Intangible Assets, net Supplier network 10.0 $ 4,000 $ ( 2,667 ) $ 1,333 Customer relationships & other intangibles 6.5 55,427 ( 34,751 ) 20,676 Developed technology 8.0 71,987 ( 23,853 ) 48,134 Patents 16.1 8,946 ( 2,936 ) 6,010 Total intangible assets $ 140,360 $ ( 64,207 ) $ 76,153 December 31, 2020 (In thousands) Weighted Average Amortization Period (in years) Gross Carrying Amount Accumulated Amortization Intangible Assets, net Supplier network 10.0 $ 4,000 $ ( 2,467 ) $ 1,533 Customer relationships & other intangibles 6.5 57,704 ( 32,056 ) 25,648 Developed technology 8.0 72,644 ( 19,295 ) 53,349 Patents 16.1 9,082 ( 2,663 ) 6,419 Total intangible assets $ 143,430 $ ( 56,481 ) $ 86,949
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	(In thousands) Annual Amortization Remaining 2021 $ 9,067 2022 17,816 2023 15,723 2024 12,744 2025 8,715 Thereafter 12,088 Total $ 76,153

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2021
ACCRUED EXPENSES [Abstract]
Schedule of Accrued Expenses	Accrued expense included the following: June 30, December 31, (In thousands) 2021 2020 Compensation and other employee-related costs $ 44,692 $ 44,948 Legal and other settlements and expenses 763 650 Accrued non-income taxes 5,473 4,952 Royalties 4,270 3,720 Other 23,255 24,064 Total accrued expenses $ 78,453 $ 78,334

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2021
EQUITY [Abstract]
Schedule of Shares Repurchased	(In thousands except for per share prices) Period Total number of shares repurchased Average Price Paid per Share Dollar amount of shares repurchased (1) Approximate dollar value of shares that may yet be purchased under the plan January 1, 2020 - March 31, 2020 1,920 $ 38.49 $ 73,902 $ 126,098 April 1, 2020 - June 30, 2020 771 39.95 30,804 95,294 July 1, 2020 - September 30,2020 — — — 95,294 October 1, 2020 - December 31, 2020 — — — 95,294 January 1, 2021 - March 31, 2021 — — — 95,294 April 1, 2021 - June 30, 2021 — — — $ 95,294 January 1, 2020 - June 30, 2021 2,691 $ 38.91 $ 104,706 (1) Inclusive of an immaterial amount of commission fees
Accumulated Other Comprehensive Income (Loss)	(In thousands) Unrealized gain/(loss) on marketable securities, net of tax Foreign currency translation adjustments Accumulated other comprehensive loss Accumulated other comprehensive loss, net of tax, at December 31, 2020 $ 5,001 $ ( 1,046 ) $ 3,955 Other comprehensive (loss)/income before reclassifications ( 3,188 ) ( 3,087 ) ( 6,275 ) Amounts reclassified from accumulated other comprehensive income, net of tax 748 — 748 Other comprehensive (loss)/income, net of tax ( 2,440 ) ( 3,087 ) ( 5,527 ) Accumulated other comprehensive loss, net of tax, at June 30, 2021 $ 2,561 $ ( 4,133 ) $ ( 1,572 ) (In thousands) Unrealized gain/(loss) on marketable securities, net of tax Foreign currency translation adjustments Accumulated other comprehensive loss Accumulated other comprehensive loss, net of tax, at December 31, 2019 $ 3,599 $ ( 6,497 ) $ ( 2,898 ) Other comprehensive (loss)/income before reclassifications 4,004 1,141 5,145 Amounts reclassified from accumulated other comprehensive income, net of tax ( 949 ) — ( 949 ) Other comprehensive (loss)/income, net of tax 3,055 1,141 4,196 Accumulated other comprehensive loss, net of tax, at June 30, 2020 $ 6,654 $ ( 5,356 ) $ 1,298
Schedule of Computation of Basic and Diluted Earnings	Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2021 2020 2021 2020 Numerator: Net income/(loss) $ 41,545 $ ( 20,837 ) $ 86,874 $ 5,112 Denominator for basic and diluted net income per share: Weighted average shares outstanding for basic 100,449 97,509 100,159 98,572 Dilutive stock options and RSUs 3,026 — 2,772 2,420 Weighted average shares outstanding for diluted 103,475 97,509 102,931 100,992 Earnings per share: Basic $ 0.41 $ ( 0.21 ) $ 0.87 $ 0.05 Diluted $ 0.40 $ ( 0.21 ) $ 0.84 $ 0.05 Anti-dilutive stock options and RSUs excluded from the calculation 1,680 11,680 2,372 6,645

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2021
STOCK-BASED COMPENSATION [Abstract]
Summary of Stock Option Activity	Option Shares (thousands) Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value (thousands) Outstanding at December 31, 2020 9,746 $ 41.33 Granted 1,662 65.48 Exercised ( 1,019 ) 34.97 Forfeited ( 349 ) 50.53 Outstanding at June 30, 2021 10,040 $ 45.65 7.3 $ 320,001 Exercisable at June 30, 2021 4,767 $ 37.08 6.1 $ 192,821 Expected to vest at June 30, 2021 5,273 $ 53.41 8.4 $ 127,180
Fair Value of Options Using Black Scholes Option Pricing Model	Six Months Ended June 30, 2021 2020 Risk-free interest rate 0.40 % - 0.84 % 0.32 % - 1.67 % Expected term (years) 4.8 4.9 Expected volatility 34.0 % 28.0 % - 33.0 % Expected dividend yield —% —%
Summary of Restricted Stock Unit Activity	Restricted Stock Units (thousands) Weighted average grant date fair value per share Weighted average remaining contractual life (years) Outstanding at December 31, 2020 3 $ 58.69 Granted 5 67.83 Vested — — Forfeited — — Outstanding at June 30, 2021 8 $ 64.36 9.3
Stock-based Compensation Schedule	Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Stock-based compensation expense $ 7,632 $ 7,311 $ 15,330 $ 14,118 Net stock-based compensation capitalized into inventory 156 115 341 210 Total stock-based compensation cost $ 7,788 $ 7,426 $ 15,671 $ 14,328

INCOME TAXES (Tables)

INCOME TAXES (Tables)	6 Months Ended
	Jun. 30, 2021
INCOME TAXES [Abstract]
Reconciliation of Statutory U.S. Federal Tax Rate to Effective Rate	Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Effective income tax rate 15.1 % 5.0 % 18.1 % 51.6 %

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
LEASES [Abstract]
Schedule of Supplemental Balance Sheet Information Related to Leases	June 30, December 31, (In thousands, except weighted average lease term and discount rate) 2021 2020 Operating lease right of use asset $ 5,821 $ 4,741 Lease liability - current 2,144 1,865 Lease liability - long-term 3,804 2,936 Total operating lease liability $ 5,948 $ 4,801 Supplemental non-cash information: Weighted-average remaining lease term (years) - operating leases 3.2 2.9 Weighted-average discount rate - operating leases 3.3 % 3.0 %
Operating Lease Expense Recognized	Three months ended Six months ended June 30, June 30, (In thousands) 2021 2020 2021 2020 Operating lease expense $ 811 $ 869 $ 1,678 $ 1,748
Future Minimum Lease Payments	(In thousands) Operating Leases Remaining 2021 $ 1,172 2022 2,153 2023 1,463 2024 993 2025 399 Thereafter 154 Total undiscounted operating lease payments $ 6,334 Less: imputed interest 386 Total operating lease liability $ 5,948

SEGMENT AND GEOGRAPHIC INFORM_2

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
SEGMENT AND GEOGRAPHIC INFORMATION [Abstract]
Schedule of Total Sales by Geographical Area	Three Months Ended Six Months Ended June 30, June 30, (In thousands) 2021 2020 2021 2020 United States $ 215,119 $ 125,154 $ 408,436 $ 283,601 International 35,897 23,768 69,924 55,898 Total net sales $ 251,016 $ 148,922 $ 478,360 $ 339,499

BACKGROUND (Narrative) (Details

BACKGROUND (Narrative) (Details)	Jun. 30, 2021item
Minimum [Member]
Number of products launched	220

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Goodwill impairment	$ 0	$ 0
Impairment of finite-lived intangible assets	0	0
Impairment of intangible assets	$ 0	$ 0

ASSET ACQUISITIONS AND BUSINE_2

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details) $ in Thousands	3 Months Ended				6 Months Ended
	Dec. 31, 2020USD ($)item	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2019USD ($)
Business Acquisition [Line Items]
Goodwill	$ 156,716					$ 155,777	$ 128,775
Acquired in-process research and development			$ 24,400		$ 24,418
Synoste Acquisition [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			25,300		25,300
Payments to Acquire Businesses, Gross			$ 22,800
Business Acquisitions, Contractual Holdback Obligation Payable Period			18 months
Acquired in-process research and development			$ 24,400
Liabilities incurred from acquisition			2,500
Synoste Acquisition [Member] | Third Anniversary [Member]
Business Acquisition [Line Items]
Contingent consideration liability			8,000		8,000
Synoste Acquisition [Member] | Fourth Anniversary [Member]
Business Acquisition [Line Items]
Contingent consideration liability			$ 4,000		$ 4,000
StelKast Acquisition [Member]
Business Acquisition [Line Items]
Inventory acquired				$ 15,300
Property, plant and equipment acquired				4,200
Intangible assets acquired				3,900
Payments to Acquire Businesses, Gross				23,800
Goodwill, Acquired During Period				4,700
Business combination, consideration transferred				28,100
Contingent consideration liability				$ 4,300
Contingent consideration payment		$ 5,000
Two Acquisitions [Member]
Business Acquisition [Line Items]
Number of acquisitions | item	2
Business combination, performance obligation period	10 years
Intangible assets acquired	$ 8,800
Weighted average useful life	4 years 2 months 12 days
Business combination, consideration transferred	$ 1,500
Contingent consideration liability	33,200
Goodwill	26,200
Liabilities incurred from acquisition	$ 300

NET SALES (Schedule of Net Sale

NET SALES (Schedule of Net Sales by Product Category) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 251,016	$ 148,922	$ 478,360	$ 339,499
Musculoskeletal Solutions [Member]
Disaggregation of Revenue [Line Items]
Net sales	230,263	143,480	442,679	326,022
Enabling Technologies [Member]
Disaggregation of Revenue [Line Items]
Net sales	$ 20,753	$ 5,442	$ 35,681	$ 13,477

MARKETABLE SECURITIES (Narrativ

MARKETABLE SECURITIES (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Payable to brokers	$ 9.7	$ 9.3
Short-term Investments [Member] | Maximum [Member]
Debt Securities, Available-for-sale [Line Items]
Contractual Maturity	1 year	1 year
Long-term Investments [Member] | Minimum [Member]
Debt Securities, Available-for-sale [Line Items]
Contractual Maturity	1 year	1 year
Long-term Investments [Member] | Maximum [Member]
Debt Securities, Available-for-sale [Line Items]
Contractual Maturity	3 years	3 years

MARKETABLE SECURITIES (Composit

MARKETABLE SECURITIES (Composition of Marketable Securities) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 190,176	$ 186,282
Gross Unrealized Gains	1,474	1,066
Gross Unrealized Losses	(6)	(4)
Fair Value	191,644	187,344
Short-term Investments [Member] | Municipal Bonds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	43,165	39,684
Gross Unrealized Gains	290	140
Gross Unrealized Losses	(6)
Fair Value	43,449	39,824
Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	93,091	97,937
Gross Unrealized Gains	1,088	817
Gross Unrealized Losses		(4)
Fair Value	94,179	98,750
Short-term Investments [Member] | Commercial Paper [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	34,504	25,543
Gross Unrealized Gains	6	4
Fair Value	34,510	25,547
Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	16,016	15,232
Gross Unrealized Gains	89	44
Fair Value	16,105	15,276
Short-term Investments [Member] | Government, Federal Agency, And Other Sovereign Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3,400	7,886
Gross Unrealized Gains	1	61
Fair Value	3,401	7,947
Long-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	451,842	353,046
Gross Unrealized Gains	2,120	5,479
Gross Unrealized Losses	(236)	(3)
Fair Value	453,726	358,522
Long-term Investments [Member] | Municipal Bonds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	77,142	70,176
Gross Unrealized Gains	168	612
Gross Unrealized Losses	(48)
Fair Value	77,262	70,788
Long-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	220,562	158,464
Gross Unrealized Gains	1,257	3,120
Gross Unrealized Losses	(77)
Fair Value	221,742	161,584
Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	154,138	124,406
Gross Unrealized Gains	695	1,747
Gross Unrealized Losses	(111)	(3)
Fair Value	$ 154,722	$ 126,150

FAIR VALUE MEASUREMENTS (Fair V

FAIR VALUE MEASUREMENTS (Fair Value of Assets and Liabilities Measured on Recurring Basis) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities	$ 47,995	$ 36,020	$ 37,270	$ 4,216	$ 9,489	$ 9,549
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	29,147		56,223
Business acquisition liabilities	47,995		37,270
Fair Value, Measurements, Recurring [Member] | Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	120,711		110,612
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	315,921		260,334
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	34,510		25,547
Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	170,827		141,426
Fair Value, Measurements, Recurring [Member] | Government, Federal Agency, And Other Sovereign Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	3,401		7,947
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	25,473		23,628
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,674		32,595
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	120,711		110,612
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	315,921		260,334
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	34,510		25,547
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	170,827		141,426
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Government, Federal Agency, And Other Sovereign Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	3,401		7,947
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities	$ 47,995		$ 37,270

FAIR VALUE MEASUREMENTS (Signif

FAIR VALUE MEASUREMENTS (Significant Unobservable Inputs in Valuation Techniques) (Details) - Fair Value, Inputs, Level 3 [Member]	6 Months Ended
	Jun. 30, 2021
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Projected year of payment	2030
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Projected year of payment	2021
Revenue Risk Premium [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	4.9
Revenue Risk Premium [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	3
Revenue Risk Premium [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	3.3	[1]
Revenue Volatility [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	15.8
Revenue Volatility [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	14
Revenue Volatility [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	14.3	[1]
Discount Rate [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	8.5
Discount Rate [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	1.2
Discount Rate [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities, measurement input	3.4	[1]
[1]	The weighted average rates were calculated based on the relative fair value of each business acquisition liability.

FAIR VALUE MEASUREMENTS (Change

FAIR VALUE MEASUREMENTS (Changes in Carrying Value of Business Acquisition Liabilities) (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurement, beginning balance	$ 36,020	$ 9,489	$ 37,270	$ 9,549
Contingent cash payments	(1,523)	(287)	(3,015)	(853)
Contractual RSU grants	(197)		(360)
Changes in fair value of business acquisition liabilities	13,870	(43)	14,128	463
Contractual payable reclassification	175	4,943	28	4,943
Fair value measurement, ending balance	$ 47,995	$ 4,216	$ 47,995	$ 4,216

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
INVENTORIES [Abstract]
Net adjustment to cost of sales related to excess and obsolete inventory	$ 3.4	$ 6.5	$ 5	$ 7.2
Excess and obsolete related provisions	7.6	8.5	11.4	10.9
Inventory sales and disposals related provisions	$ 4.2	$ 2	$ 6.4	$ 3.7

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
INVENTORIES [Abstract]
Raw materials	$ 42,080	$ 39,646
Work in process	16,771	16,446
Finished goods	172,357	173,061
Total inventories	$ 231,208	$ 229,153

PROPERTY AND EQUIPMENT (Schedul

PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 504,283	$ 493,330
Less: accumulated depreciation	(293,534)	(276,451)
Total	210,749	216,879
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	8,314	8,322
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 44,420	33,825
Useful Life	31 years 6 months
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 109,557	102,553
Instruments [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 282,245	278,930
Useful Life	5 years
Modules and cases [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 42,772	41,919
Useful Life	5 years
Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 16,975	$ 27,781
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Maximum [Member] | Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member] | Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years

PROPERTY AND EQUIPMENT (Sched_2

PROPERTY AND EQUIPMENT (Schedule of Depreciation Related to Property and Equipment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
PROPERTY AND EQUIPMENT [Abstract]
Depreciation	$ 14,506	$ 10,987	$ 26,890	$ 21,778

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS (Summary of Goodwill) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Goodwill, Beginning Balance	$ 156,716	$ 128,775
Additions and adjustments		26,043
Foreign exchange	(939)	1,898
Goodwill, Ending Balance	$ 155,777	$ 156,716

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS (Summary of Intangible Assets) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 140,360	$ 143,430
Accumulated amortization	(64,207)	(56,481)
Intangible Assets, net	$ 76,153	$ 86,949
Supplier Network [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	10 years	10 years
Gross Carrying Amount	$ 4,000	$ 4,000
Accumulated amortization	(2,667)	(2,467)
Intangible Assets, net	$ 1,333	$ 1,533
Customer Relationships & Other Intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	6 years 6 months	6 years 6 months
Gross Carrying Amount	$ 55,427	$ 57,704
Accumulated amortization	(34,751)	(32,056)
Intangible Assets, net	$ 20,676	$ 25,648
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	8 years	8 years
Gross Carrying Amount	$ 71,987	$ 72,644
Accumulated amortization	(23,853)	(19,295)
Intangible Assets, net	$ 48,134	$ 53,349
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	16 years 1 month 6 days	16 years 1 month 6 days
Gross Carrying Amount	$ 8,946	$ 9,082
Accumulated amortization	(2,936)	(2,663)
Intangible Assets, net	$ 6,010	$ 6,419

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Remaining 2021	$ 9,067
2022	17,816
2023	15,723
2024	12,744
2025	8,715
Thereafter	12,088
Intangible Assets, net	$ 76,153	$ 86,949

ACCRUED EXPENSES (Schedule of A

ACCRUED EXPENSES (Schedule of Accrued Expenses) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
ACCRUED EXPENSES [Abstract]
Compensation and other employee-related costs	$ 44,692	$ 44,948
Legal and other settlements and expenses	763	650
Accrued non-income taxes	5,473	4,952
Royalties	4,270	3,720
Other	23,255	24,064
Total accrued expenses	$ 78,453	$ 78,334

DEBT (Narrative) (Details)

DEBT (Narrative) (Details) - USD ($)	Aug. 06, 2020	Jun. 30, 2021
Citizens Bank [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	$ 125,000,000
Line of credit facility, expiration date		Aug. 3, 2022
Line of credit, borrowed amount		$ 0
Federal Funds Effective Rate [Member]
Debt Instrument [Line Items]
Credit facility, basis spread on variable rate	0.50%
LIBOR [Member] | Citizens Bank [Member]
Debt Instrument [Line Items]
Credit facility, basis spread on variable rate	1.00%
Letter of Credit [Member] | Citizens Bank [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	$ 25,000,000

EQUITY (Narrative) (Details)

EQUITY (Narrative) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)itemitem / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Mar. 11, 2020USD ($)
Class of Stock [Line Items]
Stock repurchase plan, authorized amount | $							$ 200,000
Stock repurchase plan, remaining authorized amount | $	$ 95,294	$ 95,294	$ 95,294	$ 95,294	$ 95,294	$ 126,098
Common stock, shares authorized	775,000,000
Common Class A [Member]
Class of Stock [Line Items]
Common stock, shares authorized	500,000,000		500,000,000
Number of votes per share | item / shares	1
Common Class A And B [Member]
Class of Stock [Line Items]
Number of votes per share | item	1
Common Class B [Member]
Class of Stock [Line Items]
Common stock, shares authorized	275,000,000		275,000,000
Number of votes per share | item / shares	10
Conversion of stock shares converted ratio	1

EQUITY (Schedule of Shares Repu

EQUITY (Schedule of Shares Repurchased) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		18 Months Ended
		Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
EQUITY [Abstract]
Total number of shares repurchased		771	1,920	2,691
Average Price Paid per Share		$ 39.95	$ 38.49	$ 38.91
Dollar amount of shares repurchased	[1]	$ 30,804	$ 73,902	$ 104,706
Approximate dollar value of shares that may yet be purchased under the plan		$ 95,294	$ 126,098	$ 95,294	$ 95,294	$ 95,294	$ 95,294
[1]	Inclusive of an immaterial amount of commission fees

EQUITY (Accumulated Other Compr

EQUITY (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period	$ 1,562,994	$ 1,363,366	$ 1,506,297	$ 1,402,452
Total other comprehensive income/(loss)	252	7,564	(5,527)	4,196
Total equity, end of period	1,639,273	1,336,915	1,639,273	1,336,915
Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period	(1,824)	(6,266)	3,955	(2,898)
Other comprehensive (loss)/income before reclassifications			(6,275)	5,145
Amounts reclassified from accumulated other comprehensive income, net of tax			748	(949)
Total other comprehensive income/(loss)			(5,527)	4,196
Total equity, end of period	(1,572)	1,298	(1,572)	1,298
Unrealized Gain/(Loss) On Marketable Securities, Net Of Tax [Member] | Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period			5,001	3,599
Other comprehensive (loss)/income before reclassifications			(3,188)	4,004
Amounts reclassified from accumulated other comprehensive income, net of tax			748	(949)
Total other comprehensive income/(loss)			(2,440)	3,055
Total equity, end of period	2,561	6,654	2,561	6,654
Foreign Currency Translation Adjustments [Member] | Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period			(1,046)	(6,497)
Other comprehensive (loss)/income before reclassifications			(3,087)	1,141
Total other comprehensive income/(loss)			(3,087)	1,141
Total equity, end of period	$ (4,133)	$ (5,356)	$ (4,133)	$ (5,356)

EQUITY (Schedule Of Computation

EQUITY (Schedule Of Computation of Basic and Diluted Earnings) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
EQUITY [Abstract]
Net income/(loss)	$ 41,545	$ (20,837)	$ 86,874	$ 5,112
Weighted average shares outstanding for basic	100,449	97,509	100,159	98,572
Dilutive stock options and RSUs	3,026		2,772	2,420
Weighted average shares outstanding for diluted	103,475	97,509	102,931	100,992
Basic	$ 0.41	$ (0.21)	$ 0.87	$ 0.05
Diluted	$ 0.40	$ (0.21)	$ 0.84	$ 0.05
Anti-dilutive stock options and RSUs excluded from the calculation	1,680	11,680	2,372	6,645

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Details) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)ShareBasedCompensationPlan$ / sharesshares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2021USD ($)ShareBasedCompensationPlan$ / sharesshares	Jun. 30, 2020USD ($)$ / shares	Jun. 03, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock plans | ShareBasedCompensationPlan	3		3
Intrinsic value of stock options exercised | $	$ 25	$ 12.7	$ 35.1	$ 16.2
Weighted average grant date fair value per share | $ / shares	$ 21.30	$ 12.42	$ 19.58	$ 14.29
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Unrecognized compensation expense, unvested stock options | $	$ 70		$ 70
Weighted average period of recognition, unvested stock options			3 years
Maximum contractual term			10 years
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of shares that may be issuable under stock plan	3,076,923		3,076,923
2012 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class A number of shares available for grant under the 2012 Equity Incentive Plan	10,769,230		10,769,230
Annual percentage limit for incremental shares that may be issued					3.00%
2021 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,000,000		2,000,000
2021 Plan [Member] | Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved	2,845,575		2,845,575
Class A number of shares available for grant under the 2012 Equity Incentive Plan	2,791,397		2,791,397

STOCK-BASED COMPENSATION (Summa

STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Option shares outstanding beginning balance	9,746
Option shares granted	1,662
Option shares exercised	(1,019)
Option shares forfeited	(349)
Option shares outstanding ending balance	10,040
Option shares exercisable	4,767
Option shares expected to vest	5,273
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price per share outstanding beginning balance	$ 41.33
Weighted average exercise price per share granted	65.48
Weighted average exercise price per share exercised	34.97
Weighted average exercise price per share forfeited	50.53
Weighted average exercise price per share outstanding ending balance	45.65
Weighted average exercise price per share exercisable	37.08
Weighted average exercise price per share expected to vest	$ 53.41
Weighted average remaining contractual life outstanding	7 years 3 months 18 days
Weighted average remaining contractual life exercisable	6 years 1 month 6 days
Weighted average remaining contractual life expected to vest	8 years 4 months 24 days
Aggregate intrinsic value outstanding	$ 320,001
Aggregate intrinsic value exercisable	192,821
Aggregate intrinsic value expected to vest	$ 127,180

STOCK-BASED COMPENSATION (Fair

STOCK-BASED COMPENSATION (Fair Value of Options Using Black Scholes Option Pricing Model) (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
STOCK-BASED COMPENSATION [Abstract]
Risk-free interest rate, minimum	0.40%	0.32%
Risk-free interest rate, maximum	0.84%	1.67%
Expected term (years)	4 years 9 months 18 days	4 years 10 months 24 days
Expected volatility, minimum		28.00%
Expected volatility, maximum		33.00%
Expected volatility	34.00%
Expected dividend yield

STOCK-BASED COMPENSATION (Sum_2

STOCK-BASED COMPENSATION (Summary of Restricted Stock Unit Activity) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Beginning Balance | shares	3
Granted | shares	5
Outstanding, Ending Balance | shares	8
Weighted average grant date fair value per share, Beginning Balance | $ / shares	$ 58.69
Weighted average grant date fair value per share, Granted | $ / shares	67.83
Weighted average grant date fair value per share, Ending Balance | $ / shares	$ 64.36
Weighted average remaining contractual life (years)	9 years 3 months 18 days

STOCK-BASED COMPENSATION (Stock

STOCK-BASED COMPENSATION (Stock-based Compensation Schedule) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
STOCK-BASED COMPENSATION [Abstract]
Stock-based compensation expense	$ 7,632	$ 7,311	$ 15,330	$ 14,118
Net stock-based compensation capitalized into inventory	156	115	341	210
Total stock-based compensation cost	$ 7,788	$ 7,426	$ 15,671	$ 14,328

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
INCOME TAXES [Abstract]
Acquired in-process research and development	$ 24,400	$ 24,418

INCOME TAXES (Reconciliation of

INCOME TAXES (Reconciliation of Statutory U.S. Federal Tax Rate to Effective Rate) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
INCOME TAXES [Abstract]
Effective income tax rate	15.10%	5.00%	18.10%	51.60%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	Jun. 30, 2021USD ($)
Moskowitz Family LLC Litigation [Member]
Estimated Litigation Liability	$ 0

LEASES (Narrative) (Details)

LEASES (Narrative) (Details)	6 Months Ended
	Jun. 30, 2021
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lease term	14 years
Lease term that are not recognized as right of use assets or lease liabilities	12 months
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lease term	1 year

LEASES (Schedule of Supplementa

LEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
LEASES [Abstract]
Operating lease right of use asset	$ 5,821	$ 4,741
Lease liability - current	2,144	1,865
Lease liability - long-term	3,804	2,936
Total operating lease liability	$ 5,948	$ 4,801
Weighted-average remaining lease term (years) - operating leases	3 years 2 months 12 days	2 years 10 months 24 days
Weighted-average discount rate - operating leases	3.30%	3.00%

LEASES (Operating Lease Expense

LEASES (Operating Lease Expense Recognized) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
LEASES [Abstract]
Operating lease expense	$ 811	$ 869	$ 1,678	$ 1,748

LEASES (Future Minimum Lease Pa

LEASES (Future Minimum Lease Payments) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
LEASES [Abstract]
Remaining 2021	$ 1,172
2022	2,153
2023	1,463
2024	993
2025	399
Thereafter	154
Total undiscounted operating lease payments	6,334
Less : imputed interest	386
Total operating lease liability	$ 5,948	$ 4,801

SEGMENT AND GEOGRAPHIC INFORM_3

SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details)	6 Months Ended
	Jun. 30, 2021segment
SEGMENT AND GEOGRAPHIC INFORMATION [Abstract]
Number of operating segments	1

SEGMENT AND GEOGRAPHIC INFORM_4

SEGMENT AND GEOGRAPHIC INFORMATION (Schedule of Total Sales by Geographical Area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 251,016	$ 148,922	$ 478,360	$ 339,499
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	215,119	125,154	408,436	283,601
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 35,897	$ 23,768	$ 69,924	$ 55,898